title: Can resistance to aspirin be reversed after an additional dose?
abstract: Aspirin resistance or aspirin non-responsiveness is a recently described phenomenon which has been consistently associated with an increased risk of cardiovascular events. This study was designed to determine the effects of an additional dose of 100 mg of aspirin on platelet function and proportion of aspirin non-responders using the platelet function analyzer-100 (PFA-100), in a well characterized population of stable coronary heart disease patients already on long-term aspirin treatment. Platelet function was assessed using PFA-100 in 141 patients (64.8 ± 10.1 years, 87.9% men) on long-term aspirin treatment (100 mg/day) before and 1 h after "in site" oral aspirin administration (100 mg). Prevalence of aspirin non-responders using PFA-100 was 50.7% (95% confidence interval 42.4-59). One hour after 100 mg of oral aspirin, reassessment of aspirin effects showed a prevalence of non-responders using PFA of 35.0% (95% CI 27.3-43.2) (P < 0.001 vs. pre-dose proportion). Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment.
authors: Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain.
authors: David
authors: D
authors: Vivas
authors: Esther
authors: E
authors: Bernardo
authors: Juan Carlos
authors: JC
authors: García-Rubira
authors: Luis
authors: L
authors: Azcona
authors: Ivan
authors: I
authors: Núñez-Gil
authors: Juan Jose
authors: JJ
authors: González-Ferrer
authors: Carlos
authors: C
authors: Macaya
authors: Dominick J
authors: DJ
authors: Angiolillo
authors: Antonio
authors: A
authors: Fernández-Ortiz
references: Circulation. 1995 Apr 1;91(7):2080-8
references: 7895367
references: Am J Cardiol. 2005 Aug 15;96(4):608-10
references: 16098324
references: Br J Haematol. 2004 Jan;124(1):80-5
references: 14675411
references: Eur Heart J. 2007 Jul;28(14):1702-8
references: 17569678
references: Am J Med. 2007 Jul;120(7):631-5
references: 17602938
references: J Am Coll Cardiol. 2005 Sep 20;46(6):986-93
references: 16168280
references: Thromb Res. 2007;121(3):413-8
references: 17553552
references: BMJ. 2002 Jan 12;324(7329):71-86
references: 11786451
references: J Thromb Haemost. 2003 Aug;1(8):1710-3
references: 12911581
references: Am J Cardiol. 2006 Nov 20;98(10A):11N-17N
references: 17097412
references: BMJ. 2008 Jan 26;336(7637):195-8
references: 18202034
references: J Am Coll Cardiol. 2005 Sep 20;46(6):975-83
references: 16168278
references: Circulation. 2007 Jun 26;115(25):3156-64
references: 17562955
references: Am J Cardiol. 2001 Aug 1;88(3):230-5
references: 11472699
references: J Proteome Res. 2007 Jul;6(7):2481-7
references: 17555340
references: J Thromb Haemost. 2008 Mar;6(3):444-50
references: 18194417
references: Am Heart J. 2007 Feb;153(2):175-81
references: 17239674
references: Lancet. 2006 Feb 18;367(9510):606-17
references: 16488805
references: Circulation. 2009 Dec 22;120(25):2586-96
references: 19996015
references: J Thromb Haemost. 2006 Jun;4(6):1271-8
references: 16706971
references: Diabetes. 2006 Mar;55(3):780-4
references: 16505243
references: Am J Cardiol. 2006 Jan 1;97(1):38-43
references: 16377281
references: Pharmacol Ther. 2006 Dec;112(3):733-43
references: 16919334
references: Thromb Res. 2005;115(1-2):101-8
references: 15567460
references: Curr Opin Hematol. 2002 Sep;9(5):407-15
references: 12172459
references: Circulation. 2004 Nov 9;110(19):e489-93
references: 15533872
references: Arch Intern Med. 2007 Aug 13-27;167(15):1593-9
references: 17698681
references: J Am Coll Cardiol. 2005 Oct 4;46(7):1258-63
references: 16198840
references: JAMA. 2011 Mar 16;305(11):1097-105
references: 21406646
references: Circulation. 1989 Oct;80(4):853-8
references: 2571430
references: Stroke. 2005 Feb;36(2):276-80
references: 15604423
references: J Thromb Haemost. 2005 Jun;3(6):1309-11
references: 15892858